← Russell 3000 cross-section

ETON Eton Pharmaceuticals, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-13, not restated
Healthcare

Scale

Market cap
$1.8bn
Revenue TTM
$106m
Net income TTM
$13m
Free cash flow
$15m
Composite score
48.5
Sector rank
#1703

Valuation

P / E
140.6
EV / EBITDA
85.6
EV / sales
16.9
FCF yield
0.83%
Earnings yield vs 10-yr
-4.02pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
12.0%
EBITDA margin
19.8%
ROE
27.2%
ROIC
34.2%
Revenue growth
81.5%

Insider activity, last 90 days

Net open-market
$-18.12m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Results of Operations (dollars in thousands) During the three months ended June 30, 2026, we had $37,589 in total revenues that generated a gross profit of $25,413 compared to total revenues of $18,928 during the three-month period ended June 30, 2025 that generated a gross profit of $11,924 for the period. The increase in product sales, net was primarily the result of increased sales of INCRELEX®, GALZIN®, Carglumic Acid and the addition of HEMANGEOL® product sales in the current period. …Eton Pharmaceuticals, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-13

Read the full passage →